The last glacial period of the current ice age ended about 10,000 years ago. Ice melt caused world sea levels to rise about 35 metres (115 ft) in the early part of the Holocene. In addition, many areas above about 40 degrees north latitude had been depressed by the weight of the Pleistocene glaciers and rose as much as 180 metres (591 ft) over the late Pleistocene and Holocene, and are still rising today. The sea level rise and temporary land depression allowed temporary marine incursions into areas that are now far from the sea. Holocene marine fossils are known from Vermont, Quebec, Ontario and Michigan. Other than higher latitude temporary marine incursions associated with glacial depression, Holocene fossils are found primarily in lakebed, floodplain and cave deposits. Holocene marine deposits along low-latitude coastlines are rare because the rise in sea levels during the period exceeds any likely upthrusting of non-glacial origin. Post-glacial rebound in Scandinavia resulted in the emergence of coastal areas around the Baltic Sea, including much of Finland. The region continues to rise, still causing weak earthquakes across Northern Europe. The equivalent event in North America was the rebound of Hudson Bay, as it shrank from its larger, immediate post-glacial Tyrrell Sea phase, to near its present boundaries.
If it is possible to answer this question, answer it for me (else, reply "unanswerable"): By what height did sea levels rise at the end of the last glacial period?
Ah, so.. 35 metres (115 ft)

According to East Asian and Tibetan Buddhism, there is an intermediate state (Tibetan "bardo") between one life and the next. The orthodox Theravada position rejects this; however there are passages in the Samyutta Nikaya of the Pali Canon that seem to lend support to the idea that the Buddha taught of an intermediate stage between one life and the next.[page needed]
If it is possible to answer this question, answer it for me (else, reply "unanswerable"): What book discusses bardo?
Ah, so.. Samyutta Nikaya

Some of these estimates also take into account the opportunity cost of investing capital many years before revenues are realized (see Time-value of money). Because of the very long time needed for discovery, development, and approval of pharmaceuticals, these costs can accumulate to nearly half the total expense. A direct consequence within the pharmaceutical industry value chain is that major pharmaceutical multinationals tend to increasingly outsource risks related to fundamental research, which somewhat reshapes the industry ecosystem with biotechnology companies playing an increasingly important role, and overall strategies being redefined accordingly. Some approved drugs, such as those based on re-formulation of an existing active ingredient (also referred to as Line-extensions) are much less expensive to develop.
If it is possible to answer this question, answer it for me (else, reply "unanswerable"): What happens when companies approve drugs?
Ah, so..
unanswerable